Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDAcrivon Therapeutics, Inc. Common Stock Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 2 | -$0.60 | -$0.60 | -$0.60 |
| Q2 2024 | 2 | -$0.58 | -$0.58 | -$0.58 |
| Q3 2024 | 6 | -$0.83 | -$0.57 | -$0.67 |
| Q1 2025 | 1 | -$0.66 | -$0.66 | -$0.66 |
| Q2 2025 | 1 | -$0.68 | -$0.68 | -$0.68 |
| Q3 2025 | 1 | -$0.73 | -$0.73 | -$0.73 |
| Q4 2025 | 1 | -$0.72 | -$0.72 | -$0.72 |
Acrivon Therapeutics, Inc. Common Stock Earnings Date And Information
Acrivon Therapeutics, Inc. Common Stock last posted its earnings results on Tuesday, August 13th, 2024. The company reported $-0.52 earnings per share for the quarter, topping analysts' consensus estimates of $-0.59 by $0.07. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Acrivon Therapeutics, Inc. Common Stock has generated $-3 earnings per share over the last year ($-2.74 diluted earnings per share) and currently has a price-to-earnings ratio of -3.32. Acrivon Therapeutics, Inc. Common Stock has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based on prior year's report dates.
Acrivon Therapeutics, Inc. Common Stock Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.59 | $0 | $0 | ||
| 08/13/2024 | Q2 2024 | -$0.59 | -$0.52 | 0.07 | $0 | $0 |
| 05/14/2024 | Q1 2024 | -$0.89 | -$0.73 | 0.16 | $0 | |
| 03/28/2024 | Q4 2023 | -$0.72 | -$0.86 | -0.14 | $1.88 M | |
| 11/09/2023 | Q3 2023 | -$0.72 | -$0.66 | 0.06 | $0 | |
| 08/11/2023 | Q2 2023 | -$0.68 | -$0.63 | 0.05 | $0 | |
| 05/09/2023 | Q1 2023 | -$0.64 | -$0.51 | 0.13 | $0 | |
| 03/28/2023 | Q4 2022 | -$1.09 | -$0.38 | 0.71 | $0 | |
| 09/30/2022 | Q3 2022 | -$0.47 | $0 | |||
| 06/30/2022 | Q2 2022 | -$0.44 | $0 | |||
| 03/31/2022 | Q1 2022 | -$0.56 | $0 | |||
| 12/31/2021 | Q4 2021 | -$0.34 | $0 | |||
| 09/30/2021 | Q3 2021 | -$0.17 | $0 |
Acrivon Therapeutics, Inc. Common Stock Earnings: FAQ's
When is Acrivon Therapeutics, Inc. Common Stock's earnings date?
Acrivon Therapeutics, Inc. Common Stock has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 26th, 2025 based off last year's report dates.
Did Acrivon Therapeutics, Inc. Common Stock beat their earnings estimates last
quarter?
In the previous quarter, Acrivon Therapeutics, Inc. Common Stock (:ACRV) reported $-0.52 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.59 by $0.07.
How can I listen to Acrivon Therapeutics, Inc. Common Stock's earnings conference
call?
The conference call for Acrivon Therapeutics, Inc. Common Stock's latest earnings report can be listened to online.
How can I read Acrivon Therapeutics, Inc. Common Stock's conference call transcript?
The conference call transcript for Acrivon Therapeutics, Inc. Common Stock's latest earnings report can be read online.
How much profit does Acrivon Therapeutics, Inc. Common Stock generate each year?
Acrivon Therapeutics, Inc. Common Stock (:ACRV) has a recorded net income of $0. Acrivon Therapeutics, Inc. Common Stock has generated $-2.74 earnings per share over the last four quarters.
What is Acrivon Therapeutics, Inc. Common Stock's price-to-earnings ratio?
Acrivon Therapeutics, Inc. Common Stock (:ACRV) has a price-to-earnings ratio of -3.32 and price/earnings-to-growth ratio is -1.31.